Patents by Inventor S. Sarin

S. Sarin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of amorphous atorvastin calcium salt (2:1)
    Publication number: 20050119493
    Abstract: Improved process for the preparation of amorphous atorvastatin calcium salt (2:1) comprises hydrolyzing the lactone form of atorvastatin of formula of FIG. 1 with aqueous alkali or alkaline earth metal base, extracting with organic solvent the reaction mixture and adding the same to an anti-solvent to precipitate the product and finally filtering the product to afford amorphous atorvastatin calcium (2:1). The process also comprises the preparation of amorphous atorvastatin calcium salt (2:1) from its crystalline form.
    Type: Application
    Filed: August 31, 2001
    Publication date: June 2, 2005
    Inventors: Sanjay Suri, J. Singh, S. Sarin, R. Bansal
  • Modified HGP-30 heteroconjugates, compositions and methods of use
    Patent number: 6287565
    Abstract: A heteroconjugate is formed by linking a T cell binding ligand (TCBL) such as Peptide J of &bgr;-2 microglobulin to a modified HGP-30 antigentic peptide fragment of p17 gag peptide, such as, for example A T L  Y S V  H Q R  I D V  K D T (SEQ ID NO: 5) K E A  L E K  I E E  E Q N  K S The heteroconjugate is effective in eliciting a THI directed immune response and provides a vaccine composition for treating or preventing AIDS.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: September 11, 2001
    Assignee: Cel-Sci Corporation
    Inventors: Daniel H. Zimmerman, Prem S. Sarin
  • Modified HGP-30 peptides, conjugates, compositions and methods of use
    Patent number: 6268472
    Abstract: An antigenic peptide fragment from the p17 gag protein of HIV includes a portion from HGP-30 and a contiguous portion from HGP-35 such that the peptide fragment is capable of inducing a TH1 immune response when administered to a person suffering from AIDS or at risk for AIDS. The peptide has from about 25 to about 37 amino acids, such as, for example, the sequence A T L  Y S V 1 H Q R  I D V  K D T SEQ ID NO.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: July 31, 2001
    Assignee: CEL Sci Corporation
    Inventors: Daniel H. Zimmerman, Prem S. Sarin
  • HIV-1P-17 peptide fragments, compositions containing and methods for producing and using same
    Patent number: 6258945
    Abstract: Peptide fragments of the p17 gag protein of HIV-1 from Clade C of from about 30 to about 50 amino acids, including the region extending from position 75 to position 129, raise antibodies recognizing other subtypes, including Clade A, Clade B, Clade E as well as peptides of non-coextensive but overlapping portions of the p17 gag protein. DNA sequences can be used to encode for the peptides of interest.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: July 10, 2001
    Assignee: Viral Technologies INC
    Inventors: Daniel H. Zimmerman, Prem S. Sarin
  • HIV-1 p-17 peptide fragments, compositions containing and methods for producing and using same
    Patent number: 6111068
    Abstract: Peptide fragments of the p17 gag protein of HIV-1 from Clade C of from about 30 to about 50 amino acids, including the region extending from position 75 to position 129, raise antibodies recognizing other subtypes, including Clade A, Clade B, Clade E as well as peptides of non-coextensive but overlapping portions of the p17 gag protein. DNA sequences can be used to encode for the peptides of interest.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: August 29, 2000
    Assignee: Viral Technologies, Inc.
    Inventors: Daniel H. Zimmerman, Prem S. Sarin
  • Modified HGP-30 heteroconjugates, compositions and methods of use
    Patent number: 6103239
    Abstract: A heteroconjugate is formed by linking a T cell binding ligand (TCBL) such as Peptide J of .beta.-2 microglobulin to a modified HGP-30 antigentic peptide fragment of p17 gag peptide, such as. for exampleATL YSV HQR IDV KDTKEA LEK IEE EQN KS (SEQ ID NO: 5)The heteroconjugate is effective in eliciting a THI directed immune response and provides a vaccine composition for treating or preventing AIDS.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: August 15, 2000
    Assignee: CEL-SCI Corporation
    Inventors: Daniel H. Zimmerman, Prem S. Sarin
  • Modified HGP-30 peptides, conjugates, compositions and methods of use
    Patent number: 6093400
    Abstract: An antigenic peptide fragment from the p17 gag protein of HIV includes a portion from HGP-30 and a contiguous portion from HGP-35 such that the peptide fragment is capable of inducing a TH1 immune response when administered to a person suffering from AIDS or at risk for AIDS.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: July 25, 2000
    Assignee: Cel Sci Corporation
    Inventors: Daniel H. Zimmerman, Prem S. Sarin
  • Process for the preparation and composition of a fraction containing picroside I and kutkoside
    Patent number: 5145955
    Abstract: The present invention describes a process for the preparation of a fraction, mainly containing picroside I and kurrooa, from the plant Picrorhiza kurrooa.
    Type: Grant
    Filed: October 28, 1991
    Date of Patent: September 8, 1992
    Assignee: Council of Scientific & Industrial Research
    Inventors: Bacchan S. Aswal, Ramesh Chander, Sunil K. Chatterji, Bhola N. Dhawan, Yogesh Dwivedi, Narendra K. Garg, Poonam Jain, Narinder K. Kapoor, Dinesh K. Kulshreshtha, Bishan N. Mehrotra, Gyanendra K. Patnaik, Ravi Rastogi, Jagat P. S. Sarin, Krishna C. Saxena, Shekhar C. Sharma, Shri K. Sharma, Binduja Shukla, Pradeep K. S. Visen